Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 7/20 | 0.98 |
| ▸ | DRD2 | P14416 | 7/20 | 0.98 |
| ▸ | HTR1A | P08908 | 6/20 | 0.98 |
| ▸ | HTR2A | P28223 | 5/20 | 0.98 |
| ▸ | HTR6 | P50406 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.65 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.65 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111843 | 0.98 | HTR1A (0.94) | HTR7DRD2HTR1AHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL6112584 | 0.97 | HTR1A (0.92) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL10674383 | 0.87 | HTR7 (0.75) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL10469632 | 0.86 | HTR7 (0.74) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL10468417 | 0.85 | HTR7 (0.73) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL2547292 | 0.84 | DRD2 (0.72) | HTR7DRD2HTR1AHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL10782024 | 0.83 | DRD2 (0.70) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL6244716 | 0.83 | DRD2 (0.72) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL4525951 | 0.83 | HTR1A (0.69) | HTR7DRD2HTR1AHTR2AHTR6 | |
| SCHEMBL2545276 | 0.82 | HTR1A (0.68) | HTR7DRD2HTR1AHTR2AHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563790-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2016-09-14 | — | — | EP | disclosed |
| US-9309255-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-04-12 | — | — | US | disclosed |
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | SUMITOMO DAINIPPON PHARMA CO., LTD | 2015-03-26 | — | — | US | disclosed |
| US-8921551-B2 | Process of a quaternary ammonium salt | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2563791-B1 | A PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2014-12-24 | — | — | EP | disclosed |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2014-09-11 | — | — | US | disclosed |
| US-8586737-B2 | Process of a quaternary ammonium salt using phosphate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | DAINIPPON SUMITOMO PHARMA CO, LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087830-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | HTR7 3926/4885DRD2 3458/4885HTR1A 4433/4885 |
| US-20110263847-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT | KAT5, ATP1B2, QARS1 | HTR7 3926/4885DRD2 3458/4885HTR1A 4433/4885 |
| US-20110263848-A1 | PROCESS OF A QUATERNARY AMMONIUM SALT USING PHOSPHATE | PHPT1, SLC34A2, SLC34A3 | HTR7 4466/4885DRD2 4460/4885HTR1A 4680/4885 |
| US-20140256939-A1 | PROCESS OF PREPARING A QUATERNARY AMMONIUM SALT USING PHOSPHATE | AGPS, SLC34A3, SLC34A1 | HTR7 4314/4885DRD2 4238/4885HTR1A 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.